These results suggest that the response of Calu-6 xenografts to cediranib treatment is characteristic of VEGF signalling inhibition in human tumour xenografts, whereby more prolonged treatment is required [32], which is associated with changes in vessel permeability, increased vascular normalisation [33] and inhibition of new blood vessel development [34]. Here, VEGFA is linked to neoplasm.